A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.

Trial Profile

A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs THV 02 (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors THERAVECTYS
  • Most Recent Events

    • 12 Feb 2015 New trial record
    • 04 Feb 2015 According to Theravectys media release, recruitment is planned to begin at the end of Q3 2015 in Europe and further proceed to the U.S and Japan in 2016.
    • 04 Feb 2015 According to Theravectys media release, European Medicines Agency (EMA) has granted Orphan Drug Designation to THV02 for the treatment of adult T-cell leukemia/lymphoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top